<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279561</url>
  </required_header>
  <id_info>
    <org_study_id>19-002024</org_study_id>
    <secondary_id>NCI-2020-00239</secondary_id>
    <secondary_id>19-002024</secondary_id>
    <nct_id>NCT04279561</nct_id>
  </id_info>
  <brief_title>Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>Effects of Novel Androgen Receptor Signaling Inhibitors on PSMA PET Signal Intensity in Patients With Metastatic Castrate-Resistant Prostate Cancer: A Prospective Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the effect of androgen receptor signaling inhibitors on 68Ga-PSMA-11
      PET/CT imaging in patients with castration-resistant prostate cancer that has spread to other
      places in the body (metastatic). Diagnostic procedures, such as 68Ga-PSMA-11 PET/CT, may help
      in learning how well androgen receptor signaling inhibitors work in killing
      castration-resistant prostate cancer cells and allow doctors to plan better treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To evaluate short- and long-term prostate specific membrane antigen (PSMA) imaging changes
      in response to androgen receptor signaling inhibitors (ARSI).

      SECONDARY OBJECTIVES:

      I. To correlate PSMA imaging changes with prostate specific antigen (PSA) kinetics.

      II. To correlate PSMA imaging changes with progression free survival. III. To evaluate the
      changes in PSMA PET staging (miTNM Prostate Cancer Molecular Imaging Standardized Evaluation
      [PROMISE] criteria) under ARSI.

      OUTLINE:

      Patients receive gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) intravenously (IV). After
      50-100 minutes, patients undergo positron emission tomography (PET)/computed tomography (CT)
      over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 and 2 weeks after
      initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in 68Ga-PSMA-11 lesion and total-body uptake (standardized uptake value [SUV]max and SUVmean) over time in response to androgen receptor signaling inhibitors (ARSI)</measure>
    <time_frame>Baseline, assessed up to 1 year</time_frame>
    <description>Changes are expressed in terms of percentage changes from baseline positron emission tomography (PET) (before ARSI). Will utilize mixed effect regression models to evaluate the change over time in PSMA results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA) kinetics under ARSI</measure>
    <time_frame>Baseline, assessed up to 1 year</time_frame>
    <description>Comparison of 68Ga-PSMA-11 uptake (SUVmax and SUVmean) changes over time to PSA kinetics under ARSI. Will use mixed effects regression models to correlate the PSMA and PSA time trends. These models will include the effect of time and the PSMA by time interaction effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical progression free survival (bPFS)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Correlation between 68Ga-PSMA-11 uptake (SUVmax and SUVmean) changes and time of bPFS under ARSI. Will utilize Cox-proportional hazards regression models. PSMA results will be treated as a time dependent covariate in these models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lesion size on cross sectional imaging under ARSI</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Correlation between SUVmax from 68Ga-PSMA-11 PET and lesion size on cross sectional imaging under ARSI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in staging (PSMA miTNM PROMISE criteria) under ARSI</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will utilize mixed effects regression models to evaluate the change in staging over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Assessed by Common Terminology Criteria for Adverse Events 4.03.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Castration-Resistant Prostate Carcinoma</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8</condition>
  <condition>Stage IVA Prostate Cancer AJCC v8</condition>
  <condition>Stage IVB Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Diagnostic (68GA-PSMA-11 PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 and 2 weeks after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo 68Ga-PSMA-11 PET/CT</description>
    <arm_group_label>Diagnostic (68GA-PSMA-11 PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (68GA-PSMA-11 PET/CT)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 68Ga-PSMA-11 PET/CT</description>
    <arm_group_label>Diagnostic (68GA-PSMA-11 PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>positron emission tomography scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven prostate cancer

          -  Metastatic disease: at least one known metastatic lesion

          -  Castration resistant disease with confirmed testosterone level =&lt; 50 ng/ml under prior
             first-line androgen deprivation therapy (ADT)

          -  New planned treatment with enzalutamide or abiraterone or apalutamide

          -  Willingness to undergo ARSI throughout the duration of the study as prescribed by the
             treating uro-oncologist

          -  Stated willingness to comply with continuation of ARSI treatment for the duration of
             the study

          -  Provision of signed and dated informed consent form

        Exclusion Criteria:

          -  Inability to provide written informed consent

          -  Known inability to remain still and lie flat for duration of each imaging procedure
             (about 30 minutes)

          -  Other concurrent or prior cytotoxic chemotherapy, immunotherapy, radioligand therapy,
             or investigational therapy

          -  A baseline superscan pattern on bone scan

          -  Diagnosed with other malignancies that are expected to alter life expectancy or may
             interfere with disease assessment. However, patients with a prior history of
             malignancy that has been adequately treated and who have been disease free for more
             than 3 years are eligible
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rejah Alano</last_name>
    <phone>310 206-7372</phone>
    <email>RMAlano@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kiara Booker Adame</last_name>
    <phone>310 206-7372</phone>
    <email>KMBooker@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Lira</last_name>
      <phone>310-206-7372</phone>
      <email>StephanieLira@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rajah Alano</last_name>
      <phone>310 206-7372</phone>
      <email>RMAlano@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremie Calais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

